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Purpose: We describe the outcome of revascularization procedures used to treat peripheral arterial occlusive disease
(PAOD), using population-based administrative data.
Methods: A retrospective population-based cohort study utilizing administrative databases in Ontario, Canada, was
conducted for fiscal years 1991 to 1998 to identify patients who underwent arterial bypass surgery and percutanous
transluminal angioplasty to treat PAOD. The Kaplan-Meier method was used to calculate cumulative survival rate and
amputation-free survival rate. To analyze factors that affect these rates, multivariate analysis was performed with Cox
proportional hazard models.
Results: Over the study period 15,824 patients underwent bypass operations and 11,548 underwent angioplasty. For
patients who underwent bypass surgery, 5-year cumulative survival rate was 61.5% and major amputation–free survival
rate was 83.4%, compared with 69% and 92.2%, respectively, for patients who underwent angioplasty. Male sex, older age,
diabetes, and heart disease were associated with increased risk for death after revascularization procedures. Increased risk
for major amputation after revascularization procedures was associated with male sex, older age, and diabetes, whereas
hypertension was linked to decreased risk.
Conclusion:To evaluate the long-term outcome of revascularization procedures for PAOD at the population level, survival
and major amputation–free survival rates should be used, because they provide more clinically accepted estimates
compared with the correlation between utilization rates for revascularization and amputation procedures, which have
been used to describe outcome in previously published reports in the literature. (J Vasc Surg 2003;38:279-88.)
Evaluation of the therapeutic effectiveness of interven-
tional procedures used to treat peripheral arterial occlusive
disease (PAOD) requires use of several outcome measures
that assess factors that affect patients directly (eg, survival,
amputation-free survival, quality of life, and pain relief),
and clinical measures (eg, laboratory test measurements).1
Inasmuch as limb salvage is considered the primary goal
of management of PAOD, especially in patients with critical
limb ischemia,2,3 tentative conclusions might be drawn by
examining the outcome of surgery for PAOD as measured
by the rate of lower extremity amputation.4
To identify the population-based therapeutic effective-
ness of surgery to treat PAOD, the association between
revascularization procedures and amputation rate has been
examined in several studies.5-10 The assumption in these
studies is that if revascularization procedures avert the need
for amputation in some patients, then a negative correla-
tion should exist between rates of amputation and revascu-
larization procedures.10
Several population-based studies have reported de-
creased rate of amputation in association with increased use
of revascularization procedures.8-10 On the other hand,
some studies showed no change in lower extremity ampu-
tation rate.5-7
The limitations of these studies make drawing conclu-
sions as to the effectiveness of surgery in preventing ampu-
tation extremely difficult. These limitations include the
following:
1. Estimates of procedure rates were made at the popula-
tion level rather than the patient level, and they there-
fore might reflect the incidence of multiple procedures
in the same patient.
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2. Rates of primary and secondary amputation were not
examined separately. Arterial bypass surgery (ABS) may
avert, delay, or precipitate secondary amputation, but it
has no role in primary amputation. Therefore, if the
overall reduction in amputation rate is the result of
reduction in primary amputation rather than secondary
amputation, attribution of increased use of bypass sur-
gery as a cause of this reduction is not true. Further-
more, if there is reduction in amputation rate overall but
the rate of secondary amputation is increasing, this will
give a further false impression of the effect of bypass
surgery.
3. The incidence of underlying PAOD is not known.
Determination of amputation rate in surviving patients
after revascularization procedures (amputation-free sur-
vival rate) may overcome some of these limitations, to assess
how well bypass procedures avert or delay amputation.
Furthermore, long-term survival rate after surgery is an
important outcome that can be used to evaluate revascular-
ization procedures on a population-based level.
Therefore, to describe the outcome of revascularization
procedures for PAOD using population-based administra-
tive data, survival and amputation-free survival rates after
ABS and angioplasty were determined in this retrospective
population-based study from Ontario, Canada.
METHODS
Study design
A retrospective population-based cohort study utilizing
administrative databases inOntario was conducted for fiscal
years 1991 to 1998 (April 1 of the calender year to March
31 of the following year).
Data sources
The study was conducted at the Institute for Clinical
Evaluative Science in Ontario. Case records for bypass
surgery were obtained from the Canadian Institute for
Health Information (CIHI) hospitals discharge abstract
database. This database records discharges from all acute
care hospitals in Ontario, including day surgeries. The
CIHI database contains information on patient demo-
graphics, diagnosis, and procedures. The diagnosis codes
are based on the International Classification of Disease, 9th
revision (ICD-9),11 and treatment codes are based on the
Canadian Classification of Diagnostic, Therapeutic and
Surgical Procedures (CCP).12 Because not all percutaneous
transluminal angioplasty (PTA) procedures are in-patient
procedures, the CIHI database cannot provide full infor-
mation about them. Therefore the Ontario Health Insur-
ance Plan (OHIP) database was used to determine PTA
procedures. This database records claims paid for health
care providers by the Ontario Ministry of Health, which is
the sole source of health care reimbursement in the prov-
ince of Ontario. The diagnosis and procedure codes are
based on Ontario Ministry of Health fee-for-service and
diagnosis codes.13 The OHIP database lacks demographic
information on patients. Therefore it was linked to the
Ontario Registered Persons Data Base (RPDB), which
records demographic information that describes persons
who are or were entitled to medical services under OHIP.
Each patient in these databases (CIHI, OHIP, RPDB) has
the same unique encrypted identifier.
Identification of cases
ABS procedures. Using the CIHI database, we ob-
tained discharge abstracts for all patients 45 years or older
who were discharged between April 1, 1991, and March
31, 1999, with a procedure code for lower extremity ABS
(CCP codes 51.25, 51.29). Records with CCP code 51.25
were considered as aorto-ilio-femoral bypass procedures,
and records with CCP code 51.29 were considered as other
peripheral bypass procedures, which implies infrainguinal
reconstruction. To ensure that only procedures for PAOD
were included, records with a primary diagnosis code indi-
cating abdominal aortic aneurysm (ICD-9 codes 441.3-
441.7), iliac artery aneurysm (ICD-9 codes 442.0, 442.2),
or lower extremity artery aneurysm (ICD-9 code 442.3)
were excluded. Duplicate records, which are defined as a
record with similar unique encrypted identifier, admission
date, procedure, and diagnosis codes, were excluded.
Records with missing unique encrypted identifier also were
excluded. To identify characteristics of patients undergoing
these procedures, the data were sorted by unique encrypted
identifier to transform them to the patient level. Co-mor-
bid conditions, ie, diabetes mellitus (ICD-9 code 250),
hypertension (ICD-9 code 401-405), and coronary artery
disease (ICD-9 codes 410-414), were identified from the
records for each patient.
PTA procedures. The OHIP claim records at the
Institute for Clinical Evaluative Science for fiscal year 1991
are not complete; therefore the decision was made to
include only records for fiscal years 1992 through 1998.
Claims for all patients made between April 1, 1992, and
March 31, 1999, with a service code for lower extremity
PTA (J025) were obtained from the OHIP database. Ser-
vice code J025 is not specific for lower extremity angio-
plasty; it was also used for renal angioplasty until 1994 and
is still in use for upper extremity and carotid PTA.
Although not all physicians record the diagnosis on
OHIP claims, records with diagnosis codes indicating renal
vascular anomalies (code 593.8), hypertensive renal disease
(code 403), renal failure (codes 584, 584), transient isch-
emic attack (code 435), or chronic arteriosclerotic cerebro-
vascular disease (code 437) were excluded in an effort to
decrease the number of renal and carotid angioplasty cases.
To obtain the demographic features of patients who under-
went PTA, the claim records were linked to the RPDB by
the unique encrypted identifier. Any record for patients
younger than 45 years was excluded. Duplicate records,
defined as a record with similar unique encrypted identifier,
service date, procedure, and diagnosis codes, were ex-
cluded. Records with missing unique encrypted identifier
also were excluded. The data were then sorted by the
unique encrypted identifier to transform them to the pa-
tient level.
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Outcome of revascularization procedures. The fol-
low-up period was defined as time from the admission date
for ABS and the service date for PTA until readmission for
major amputation, death, or March 31, 1999.
After identifying patients who underwent ABS or PTA
as described, these patients were followed up in the CIHI
database from the date of surgery (admission date for ABS,
either aorto-ilio-femoral or other peripheral bypass proce-
dure) or from the PTA service date until the date of major
amputation (admission date for amputation) with the
unique encrypted identifier. Major amputation was defined
as through-ankle (CCP code 96.13), below-knee (CCP
code 96.14), or above-knee (CCP code 96.15). In addi-
tion, these patients were followed up from the date of the
procedure until the date of death by linking patient records
to the RPDB with the unique encrypted identifier.
Data validation
To validate coding for PAOD surgical procedures, 300
discharge abstract records from the CIHI database with
ABS codes and a hospital code indicating Sunnybrook and
Women’s College Health Science Centre, a major teaching
hospital in Toronto, were randomly selected over the study
period. These records were compared with the correspond-
ing patient charts from this hospital to assess level of
agreement for procedure and comorbid condition coding.
The percentage of CIHI records matched with patient
charts was calculated for both ABS and amputation records.
With patient charts as the standard, we calculated sensitiv-
ity, specificity, positive and negative predictive values, and
overall accuracy, to describe validity and accuracy for co-
morbid condition recording in the matched CIHI records.
Sensitivity is the proportion of patient charts with the
comorbid diagnoses that have a positive CIHI recording
for the diagnoses, whereas specificity is the proportion of
charts without the comorbid diagnoses that have a negative
CIHI recording for the diagnoses. Accuracy and validity
refer to how closely a CIHI record of having or not having
a comorbid condition corresponds with the presence or
absence of such a condition.
Statistical analysis
Survival rate after revascularization procedures.
The Kaplan-Meier method (product-limit method)14 was
used to estimate cumulative survival rate after ABS and
PTA. Survival was defined as time in years from the proce-
dure date until death. If a patient had undergonemore than
one procedure, follow-up was started from the first proce-
dure. Data for patients who did not die before the end of
study (March 31, 1999) were considered censored data.
Patients who underwent ABS were subdivided into
aorto-ilio-femoral bypass and other peripheral bypass
groups. Survival rate was calculated for these groups in a
similar way and were compared with the log-rank test.
Major amputation–free survival rate after revascu-
larization procedures. The Kaplan-Meier method (prod-
uct-limit method)14 was used to estimate cumulative major
amputation–free survival rate after both ABS and PTA.
Major amputation–free survival was defined as time in
years from the procedure until major amputation. If a
patient had undergone more than one procedure, fol-
low-up was started from the first procedure. Also, if a
patient had more than one major amputation after the
procedure, the first amputation was counted as the event.
Data for patients who did not experience the event before
the end of the study (March 31, 1999) and data for patients
who died before an amputation was performed were con-
sidered censored data. Patients who underwent ABS were
subdivided into aorto-ilio-femoral bypass and other periph-
eral bypass groups. Major amputation–free survival rate was
calculated for these groups in a similar way and were
compared with the log-rank test.
A Cox proportional hazards model15,16 was used to
determine the effect of age at the time of the procedure,
gender, and comorbid condition (diabetes mellitus, hyper-
tension, coronary artery disease) on survival rate and major
amputation–free survival rate after ABS, whether aorto-ilio-
femoral or other peripheral bypass procedure. Because the
OHIP database lacks information on comorbid conditions,
the Cox proportional model was fitted only for age and sex
after PTA. Age was entered into the model as a continuous
variable. Other variables, eg, sex (male, female) and comor-
bid conditions (present or absent) were entered into the
model as dichotomous variables. All variables were entered
into the model simultaneously without use of stepwise or
conditional procedures.
All P values reported were two-tailed and were consid-
ered significant at .05.
Statistical analyses were performed with Statistical Ap-
plications Software, version 8 (SAS Institute, Cary, NC).
RESULTS
Baseline characteristics
Patient baseline characteristics are summarized in Table
I. Over the study period 15,824 patients underwent bypass
operations and 11,548 patients underwent angioplasty.
More than one third of patients were women. Patients who
underwent PTA were younger than those who underwent
other peripheral bypass surgery (P  .0001). On the other
hand, patients who underwent aorto-ilio-femoral bypass
surgery were younger than those who underwent angio-
plasty (P  .0001). Prevalence of diabetes, hypertension,
and coronary artery disease in patients who underwent PTA
was not recorded because the OHIP database lacks detailed
information on comorbid conditions.
Data validation
Accuracy for recording bypass surgery in the CIHI
database records, as compared with patient charts, was
91.3%. Although specificity for recording comorbid condi-
tions was high, sensitivity was low. Overall accuracy for
recording comorbid conditions was moderate (Table II).
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Survival after revascularization procedures
Mean follow-up for patients who underwent ABS was
3.1  2.4 years. During follow-up 5074 patients died.
Five-year survival rate for these patients was 61.5% 0.38%
(Fig 1). When survival rate was compared between patients
who underwent aorto-ilio-femoral bypass and those who
underwent other peripheral bypass procedures, 5-year sur-
vival rate was 74.7%  0.8% versus 56.8%  0.6%, respec-
tively (P  .0001, log-rank test) (Fig 1).
Increased risk for death after ABS was associated with
increased age, male sex, coronary artery disease, and diabe-
tes. On the other hand, hypertension was associated with
decreased risk (Table III).
For patients who underwent PTA, mean follow-up was
3.1  2 years. During follow-up 2556 patients died. Five-
year survival rate was 68.9%  0.6% (Fig 2). Risk for death
after PTA was higher in men and older patients (Table III).
Major amputation–-free survival after
revascularization procedures
Freedom from any major amputation in surviving pa-
tients after arterial bypass surgery at 5 years was 83.4% 
0.37% at 5 years (Fig 3). It was significantly better at 5 years
in patients who underwent aorto-ilio-femoral bypass
(94.0%  0.5%) than in those who underwent other pe-
ripheral bypass procedures (79.4% 0.5%; P .0001) (Fig
3).
Increased risk for amputation after ABS was associated
with increased age, male sex, and diabetes. On the other
hand, hypertension was associated with decreased risk (Ta-
ble IV).
Five-year major amputation–free survival for patients
who underwent PTAwas 92.2% 0.34% (Fig 4). Increased
risk for major amputation after PTA was associated with
increased age and male sex (Table IV).
DISCUSSION
This study was undertaken to determine the outcome
of revascularization procedures for PAOD on a population
basis. The overall 5-year survival rate for patients who
underwent ABS was 61.5%, compared with 69% for those
who underwent PTA. The higher survival rate in the PTA
group might be attributed to a higher proportion of pa-
tients with mild to moderate athersclerotic disease as com-
pared with the surgery group. Dormandy et al17 showed a
70% 5-year survival rate for patients with intermittent clau-
dication, and other studies have reported a 38% to 48%
5-year survival rate for patients with critical leg ischemia
treated surgically.18 However, because of absence of clini-
cal indications (intermittent claudication vs critical leg isch-
emia) for intervention in the databases, comparison be-
tween survival rates for these procedures with previously
published reports is not possible.
Table I. Characteristics of patients who underwent lower extremity revascularization procedures secondary to peripheral
occlusive disease, in Ontario, fiscal years 1991-1998
ABS AIF OPB PTA*
Number of patients 15,824 4053 12,072 11,548
Mean age (y) (SD) 66.3 (11.9) 61.8 (10.3) 67.7 (11.9) 65.6 (10.1)
Sex (% F/M) 37.6/62.4 42/58 36.1/63.9 40.2/59.8
Diabetes (%) 4447 (28.1) 665 (16.4) 3851 (31.9) —
Hypertension (%) 3497 (22.1) 969 (23.9) 2607 (21.6) —
Coronary artery disease (%) 3766 (23.8) 960 (23.7) 2885 (23.9) —
ABS, Arterial bypass surgery; AIF, aorto-Iliac-femoral bypass surgery; OPB, other peripheral bypass surgery; PTA, percutanous transluminal angioplasty.
*Fiscal years 1992-1998.
Table II. Level of agreement between matched charts for patients who underwent arterial bypass surgery with
corresponding CIHI discharge abstract records for comorbid conditions
Comorbid condition
Sensitivity*
(%)
Specificity†
(%)
Positive
predictive
value‡
(%)
Negative
predictive
value§
(%)
Overall
accuracy
(% agreement)
Diabetes 56.6 82.1 70.8 71.1 71.0
Hypertension 52.1 89.1 84.4 62.0 69.3
Coronary artery disease 42.4 94.9 86.2 68.5 72.3
CIHI, Canadian Institute for Health Information; TP, True positive results; TN, true negative results; FP, false positive results; FN, false negative results.
*Sensitivity  TP  100%/(TP  FN).
†Specificity  TN  100%/(TN  FP).
‡Positive predictive value  TP  100%/(TP  FP).
§Negative Predictive Value  TN  100%/(TN  FN).
Overall accuracy  (TP  TN)  100%/(TP  TN  FP  FN).
JOURNAL OF VASCULAR SURGERY
August 2003282 Al-Omran et al
Furthermore, when ABS was subdivided to the two
procedure codes, CCP code 51.25 (aorto-ilio-femoral by-
pass, which includes aortofemoral, aortoiliac, aortopopli-
teal, and iliofemoral bypass) and CCP code 51.25 (other
peripheral bypass, which includes distal bypass surgery and
extra-anatomic bypass), 5-year survival rate in patients who
underwent aorto-ilio-femoral bypass was 75%, compared
with 57% for those who underwent other peripheral bypass
procedures. Again, because of lack of procedure specificity,
comparison with other reported rates is difficult. However,
we hypothesized that most procedures under CCP code
51.25 are aortofemoral surgeries and that most procedures
under CCP code 51.29 are distal bypass procedures. Five-
year survival rate after aorto-ilio-femoral bypass was in the
range of the reported 5-year survival rate after aortobifemo-
ral bypass, ranging from 68% to 80%.19-22 Also, 5-year
survival rate after other peripheral bypass procedures was in
the range of the reported 5-year survival rate after infrain-
guinal arterial reconstruction bypass, ranging from 38% to
59%.23-25
Age,26-28 male sex,27,29 coronary artery disease,26,28,30
diabetes,19,22,30-33 and hypertension30,33 have all been re-
ported as predictors for increased mortality in patients with
PAOD. In this study, multivariate models were used to
account for these risk factors simultaneously in predicting
death after revascularization procedures. Age, male sex,
diabetes, and coronary artery disease were associated with
increased risk for death after revascularization procedures.
However, hypertension was associated with decreased risk,
possibly because hypertension is underreported in the da-
tabase.
Five-year major amputation–free survival rate for pa-
tients who underwent ABS was 83.4%, compared with
92.2% for those who underwent PTA. This might be ex-
plained by the suggestion that PTA procedures are mostly
performed in patients with intermittent claudication,
whereas bypass surgeries are usually performed in patients
with critical ischemia.
When bypass surgery was subdivided to aorto-ilio-
femoral bypass and other peripheral bypass groups, 5-year
major amputation–free survival rates were 94% and 79%,
respectively. These finding can be explained in that aorto-
ilio-femoral bypass, which was performed to treat aortoiliac
occlusive disease, is associated with better long-term results
than is surgery (ie, other peripheral bypass procedures)
performed to treat distal arterial disease.
The only population-based study examining amputa-
tion-free survival rate after revascularization procedures was
by Hallett et al.9 This group studied estimated major
amputation–free survival in 271 patients without diabetes
Fig 1. Kaplan-Meier survival curves after bypass surgery. ABS, Arterial bypass surgery; AIF, aorto-iliac-femoral bypass
surgery; OPB, other peripheral bypass surgery. Note: Standard error is less than 1% for each point in the curves.
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and 172 patients with diabetes who underwent revascular-
ization procedures to treat PAOD. Estimates at 5-years
were 95% and 87%, respectively, for patients without or
with diabetes. This study has many limitations, including
small sample size; small geographic area, which may have
led to selection bias for the population studied; and failure
to differentiate between patients who underwent bypass
surgery, including aortoiliac and infrainguinal procedures,
and those who underwent PTA.
Age,1,17 male sex,1,29 and diabetes34-41 are associated
with increased risk for development and local progression
of PAOD. Although hypertension is associated with in-
creased risk for PAOD,34-38,42-44 its role in progression of
the disease is not well-established.30 Furthermore, age and
Table III. Risk factors for death after revascularization procedures to treat POAD
Risk factor Risk ratio
95% confidence
interval P*
Arterial bypass surgery
Age (per each year of age) 1.054 1.051-1.057 .0001
Male sex 1.26 1.19-1.33 .0001
Hypertension 0.91 0.85-0.97 .0038
Coronary artery disease 1.48 1.40-1.57 .0001
Diabetes 1.68 1.59-1.78 .0001
Aorto-iliac-femoral bypass surgery
Age (per each year of age) 1.066 1.059-1.074 .0001
Male sex 1.21 1.06-1.39 .0052
Hypertension 0.92 0.79-1.08 .3006
Coronary artery disease 1.52 1.32-1.74 .0001
Diabetes 1.56 1.33-1.83 .0001
Other peripheral bypass surgery
Age (per each year of age) 1.048 1.045-1.051 .0001
Male sex 1.24 1.17-1.33 .0001
Hypertension 0.91 0.84-0.98 .011
Coronary artery disease 1.50 1.41-1.61 .0001
Diabetes 1.63 1.53-1.73 .0001
Percutanous transluminal angioplasty
Age (per each year of age) 1.057 1.052-1.061 .0001
Male sex 1.25 1.16-1.36 .0001
POAD, Peripheral occlusive arterial disease.
*Cox proportional hazards model.
Fig 2. Kaplan-Meier survival curve after percutanous transluminal angioplasty in 11,584 patients. Note: Standard error
is less than 1% for each point in the curve.
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diabetes are well-documented factors for increased risk for
amputation in patients with PAOD.36,45-47 The effect of
these risk factors on amputation rates after revascularization
procedures was examined in multivariate statistical models.
In all models, age, male sex, and diabetes were associated
with increased risk for amputation. In some models, coro-
nary artery disease was associated with increased risk for
amputation. On the other hand, all models showed hyper-
tension associated with decreased risk for amputation, pos-
sibly because hypertension is underreported in the data-
base. However, historically, plasma volume expansion has
been used for patients with critical leg ischemia to increase
blood pressure, thereby improving distal blood flow.48
Maintaining adequate blood pressure is important for limb
perfusion, and aggressive blood pressure treatment may
decrease limb perfusion and thus worsen ischemic pain.1
Therefore this association between hypertension and de-
creased risk for amputation may be true, but requires
further study.
In evaluation of these results, several potential limita-
tions related to use of administrative databases should be
considered. First, service codes used in the OHIP database
have not kept pace with developments in medical technol-
ogy and intervention. Therefore OHIP is limited to the
degree to which certain procedures can be specified. For
example, service code J025, which was used to identify PTA
cases, is not specific for lower extremity angioplasty, but
was also used for renal angioplasty until 1994 and is still in
use for upper extremity and carotid PTA. Although an
effort was made to decrease the number of renal and carotid
angioplasty cases by excluding the records with diagnosis
codes indicating diseases other than PAOD, only 73 of
17,879 records were excluded. Most physicians do not
record the diagnosis on the claims statement, because in
most cases a diagnosis is not required for payment.49 How-
ever, an expert consultant suggested that more than 85% of
the cases included are indeed PAOD (Dr Stuart Bell, De-
partment of Diagnostic Imaging, University of Toronto,
2002).
Second, procedure codes in the databases lack proce-
dure specification. Service code J025 is used for both
aortoiliac and distal PTA. Similarly, CCP codes 51.25 and
51.29 lack procedure specification; 51.25 is used to code
aortofemoral, aortoiliac, aortopopliteal, and iliofemoral to-
gether, and 51.29 is used for coding both distal and extra-
anatomic bypass surgery to treat PAOD. Furthermore,
clinical indications for these procedures, whether per-
formed to treat intermittent claudication or critical isch-
emia, are not recorded in the databases. These factors
combined make comparison with other clinical studies
difficult, because each procedure has its own indications
and natural history.
Fig 3. Kaplan-Meier major amputation–free survival curves after bypass surgery. ABS, Arterial bypass surgery; AIF,
aorto-iliac-femoral bypass surgery; OPB, other peripheral bypass surgery. Note: Standard error is less than 1% for each
point in the curves.
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Finally, the databases do not specify which limb the
procedure was performed on. Thirty percent of patients
with critical leg ischemia require an intervention in the
contralateral leg within 5 years.50 Therefore amputation-
free survival rates may be underestimated if the revascular-
ization procedure was performed on one limb and subse-
quent amputation was performed on the other limb later.
In summary, this study documents the relatively low
long-term survival rates associated with revascularization
procedures at the population level. Amputation-free sur-
Table IV. Risk factors for major amputation after revascularization procedures to treat POAD
Risk factor Risk ratio
95% confidence
interval P*
Arterial bypass surgery
Age (per each year of age) 1.030 1.026-1.035 0.0001
Male sex 1.22 1.12-1.34 0.0001
Hypertension 0.84 0.75-0.93 0.0007
Coronary artery disease 1.14 1.04-1.26 0.0208
Diabetes 2.50 2.28-2.73 0.0001
Aorto-iliac-femoral bypass surgery
Age (per each year of age) 1.024 1.009-1.040 0.0017
Male sex 1.65 1.21-2.24 0.0014
Hypertension 0.90 0.64-1.26 0.5373
Coronary artery disease 0.99 0.72-1.39 0.9813
Diabetes 2.46 1.80-3.36 0.0001
Other peripheral bypass surgery
Age (per each year of age) 1.021 1.017-1.026 0.0001
Male sex 1.14 1.03-1.25 0.0082
Hypertension 0.86 0.76-0.96 0.0071
Coronary artery disease 1.20 1.08-1.33 0.0005
Diabetes 2.23 2.03-2.44 0.0001
Percutanous transluminal angioplasty
Age (per each year of age) 1.035 1.027-1.044 0.0001
Male sex 1.44 1.22-1.70 0.0001
POAD, Peripheral occlusive arterial disease.
*Cox proportional hazards model.
Fig 4. Kaplan-Meier major amputation–free survival curve after percutanous transluminal angioplasty in 11,584
patients. Note: Standard error is less than 1% for each point in the curves.
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vival rate after revascularization can be used to describe the
postoperative clinical course. In addition, it provides more
clinically accepted estimates of long-term outcome of re-
vascularization procedures at the population level, which
may be of great interest to patients undergoing revascular-
ization procedures to treat PAOD. Physicians could use
survival and amputation-free survival rates and factors that
influence them to explain to patients the long-term out-
come of revascularization procedures. Furthermore, the
findings of this study provide some initial parameters for
investigating the effect of revascularization procedures on
amputation rate. This could be achieved by repeating a
similarly designed study in Ontario over the next decade
and comparing the outcomes for these two periods.
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